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depression and improve parent e child relationship, but it is not
effective on reducing of mothers Perceived stress.
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Extended Abstract
Introduction: The first description of p53 protein is in 1979 and
since that time there have been more than 35 000 papers published on
this topic. However even after 30 years after its discovery, it is still
somewhat of a mystery. The gene encodes transcription factor p53
is TP53, one of the most commonly altered genes in human cancers.
P53 protein plays a central role to regulate cell cycle progression, dif-
ferentiation, senescence, DNA repair, and apoptosis. In response of
DNA damage or other stress signals, p53 activity is up-regulated
and a series of biological events cascade is initiated that eventually
results in prevention of tumor development and expansion. Recent
studies showed, about 50% of human cancers have p53 mutation
but the frequency varies considerably between cancer types, ranging
from ~10% in hematopoietic malignancies to 50e70% in ovarian,
colorectal and head and neck cancers. Mutations in p53 dissolve its
normal tumor suppressor functions finally contributing to the survival
and/or amplification of aberrant cells with poorly differentiated phe-
notypes. Cancer cells with mutant p53 are associated more aggressive
disease, increased resistance to radiation therapy and chemotherapy,
with poor prognosis of the disease.
Dominant negative mutation of TP53 gene: The presence of
p53 mutation in cell does not necessarily mean it loses p53 activity,
when a cell has a wild type allele together with the mutant one. In
this heterozygous state it should be known that, this cell may con-
tain a trans dominant mutation with reduced p53 activity and then
confer a growth advantage and other tumorogenesis signs. Moreover,
p53 mutant cancer cells which contain a dominant-negative activity
or Gain Of Function (GOF) activity that inactives hetero-oligomers
of the mutants with the wild-type protein. Dominant-negative p53
mutation results in the total abrogation of p53 protein function,
even if cells still have wild-type protein expression. Increasing evi-
dence showed that many p53 mutant cells also gain new oncogenic
properties that are independent from wild-type one. p53 mutants that
promote tumor progression or/and resistance to therapies become
the most common prognostic marker for both tumor recurrence
and death caused by cancer. These mutation reduce the ability of
the wild type p53 to bind to its target gene responsive element.
For example, in one study, mutant TP53 was found in 24 of 92
(26.1%) endometrial cancers, in which 14 cases showed dominant-
negative activity that was associated with progressed stages, non
endometrioid type tumors. It showed, the presence of a dominant
negative mutant p53 was related to poor outcomes, suggesting that
dominant negative mutant TP53 should play a pivotal role in the
progression of endometrial cancer.
TP53 cancer gene therapeutic way: On the result of many
researches that p53 inactivation is common in human cancers, it
may be assumed that reactivation of p53 and functional restoration
of the p53 tumor suppressor pathway is a potential and detrimental
therapeutic way against cancer. Gene therapy using wild-type p53,delivered by adenovirus vectors, is now widespread and other bio-
logic approaches like the development of oncolytic viruses designed
to replicate and kill only p53 defective cells. The other way is the
development of siRNA and antisense RNA's that activate p53 by
inhibiting the function of the negative regulators Mdm2, MdmX,
and HPV E6 is effective too. In conclusion Adenovirus-based p53
gene therapy as well as using small molecules include PRIMA that
can restore the transcriptional function to mutant p53 cell, or NUT-
LIN and RITAwhich interfere with MDM2-directed p53 degradation,
have been tested in a preclinical stage and some of these approaches
are currently in clinical development.
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Extended Abstract
Introduction: Breast cancer is the most common cause of malig-
nancy and cancer mortality among women in the less developed
(LDCs) and more developed (MDCs) countries worldwide. Global sta-
tistics indicate the annual incidence of breast cancer is increasing and
this is happening faster in countries with a low incidence rate of breast
cancer. Both environmental and genetic factors are involved in the risk
of breast cancer. Genetic risk factors such as variations in TOX3 which
contribute to the liability play an important role in the development of
the disease. In regard to the latter, genome wide association studies
(GWAs) has identified low penetration but high frequency disease-
associated single nucleotide polymorphisms (SNP) in a number of
genes, such as the HMG-box nuclear protein TOX high mobility group
box family member 3 (TOX3). TOX3, also known as TNRC9, is a
non-histone chromatin protein including anuclearlocalization signal
(NLS) and a high mobility group (HMG)-box domain followed by a
C-terminal polyglutamine stretch. The HMG-box super family is
described by a ~80 amino acid DNA-binding domain, and individual
members function such as regulation of gene expression, chromatin
remodeling, DNA repair, and genomic stability.
Previous data indicated that TOX is a sequence-independent
HMG-box DNA-binding protein.TOX3 maps to chromosome 16q12
and consists of seven exons. TOX3 is a region regularly lost in breast
cancers and is involved in the risk of spreading breast cancer. How-
ever, there is little data on TOX3 and breast cancer although TOX3
has profound effects on regulation of cellular activity during initia-
tion, maintenance, or developing of cancer.
TOX3 is highly expressed in the central nervous system (CNS), in
the ileum, and within the brain in the frontal and occipital lobe in nor-
mal human tissues as well as in breast tumor at a higher level than in
normal tissue. TOX3 risk-allele carriers have been reported to develop
more lobular breast tumors, and patients with this SNP who develop
luminal A (LumA) breast tumors have shorter overall survival.
TOX3 has calcium-dependent transcriptional activity and is a co-fac-
tor of cAMP response element (CRE)-binding protein (CREB) and
CREB-binding protein (CBP). RNAi-mediated knockdown of the
endogenous TOX3 resulted in significant reduction of calcium-
induced c-fos expression and complete inhibition of calcium
6 Abstracts - 1st International Nastaran Cancer Symposium-2015 / Journal of Cellular Immunotherapy 1 (2015) 1e45activation of the c-fos promoter. The c-fos proto-oncogene has been
implicated as a regulator of estrogen-mediated cell proliferation.
Apoptosis and cell protection: TOX3 was demonstrated to be
expressed downstream of a cytoprotective cascade together with
CITED1, a transcriptional regulator that does not bind directly to
DNA and enhances transcription mediated by diverse transcription
factors, such as estrogen receptors, SMAD, or early growth response
(EGR) 2. CITED1 expression parallels with estrogen receptors ERa
and ERb.
TOX3 over-expression protects neuronal cells from cell death
caused by endoplasmic reticulum stress or BAX over-expression
through the induction of repression of pro-apoptotic transcripts and
anti-apoptotic transcripts, which associates with enhanced transcrip-
tion implicating isolated estrogen-responsive elements (ERE) and
estrogen-responsive promoters. TOX3 also interacts with native
CREB and induces the CREB-responsive BCL-2 promoter. Co-
expression of CITED1 inhibits the CREB-responsive BCL-2 pro-
moter and by contrast, co-expression of CREB inhibits TOX3-medi-
ated transcription from the estrogen-responsive complement C3
promoter. Results have suggested that TOX3 can mediate cytoprotec-
tive transcription from the BCL-2 promoter or the complement C3
promoter, based on the predominance of either phosphorylated
CREB or CITED1 within the transcriptionally active complex.
Regulation of estrogen: TOX3 is also shown to regulate Trefoil
Factor Family 1 (TFF1), the estrogen-regulated protein, in an estro-
gen-independent and tamoxifen-insensitive way. TFF1, a small cys-
teine-rich secreted protein, is normally expressed at highest levels
in the mucosa of the gastrointestinal tract and also is extensively
expressed at high levels in malignant breast epithelial cells where
its expression is regulated by estrogen. Even in the absence of estro-
gen, TFF1 was upregulated by TOX3. Additionally, TOX3 induces
enhancer RNAs that have been involved in TFF1 gene regulation.
FOXA1 and ESR1: It is known that a SNP near its 5ʹend and pro-
moter appears to be strongly associated with breast cancer suscepti-
bility. Breast cancereassociated SNPs are also enriched for FOXA1
and ESR1 transcription factorebinding sites and H3K4me1 histone
modification. This SNP alters a FOXA1, a protein required for estro-
gen receptor-a (ER) function, with disease susceptibility associated
with enhanced FOXA1 binding, disordered enhancer function, and
a reduce in TOX3 gene expression. The data may offer a validation
for prophylactic treatment of high-risk patients with FOXA1
inhibitors.
TOX3 and bone metastasis of breast cancer: Some TOX3
expressing tumors are linked with adverse outcome, and increased
expression of TOX3 mRNA that has been involved in breast cancer
metastatic to bone. In microarray analysis, between the genes upregu-
lated by TOX3 was the well-investigated pro-metastatic gene CXCR4.
It has been indicated that IGF-1 cooperates with CXCR4 signaling to
advance bone marrow metastasis of breast cancer, potentially one fac-
tor in the aggressive behavior of LumB tumors. Since CXCR4 is
upregulated by TOX3 and is highly expressed in LumB tumors,
this could improve the migratory properties of MCF-7 cells. There-
fore, IGF-1 could play a role in regulation of TOX3 expression.
MCF-7 cells treated with IGF-1 indicated significant, albeit modest,
upregulation of TOX3 expression, as well as the known IGF-1 target
gene GAPDH.
TOX3+ and therapeutic modalities for breast cancer: TOX3
expression is regarded a tumor promoter rather than a tumor sup-
pressor in breast cancer. It has been suggested that TOX3 expres-
sion decreases in breast cancer and is correlated with the disease
risk. Furthermore, TOX3 has the potential to regulate ER targetgene expression in the appearance of limiting concentrations of
estrogen. This potential property underlines the treatment modal-
ities for TOX3+ breast cancer. It is also suggested that TOX3 and
related biomarkers, such as SCUBE2, TFF1, TFF3, AGR2, CEA-
CAM6, TSPAN1 or CXCR4 are helpful for the diagnosis, prognosis
and treatment as well as classification of different breast cancer
subtypes. Knocking down of TOX3 by siRNA suggests that even
low levels of TOX3 may affect estrogen activation of the TFF1
gene.
Additionally, estrogen treatment in cells over-expressing TOX3
results in a hyper-responsive TFF1 gene expression. Expression of
TOX3 may be implicated in the resistance to endocrine therapy which
may occur in some LumB cancers. In this respect, cells over-express-
ing TOX3 had a better capability to survive under estrogen-deprived
conditions.
IGF-1 treatment in MCF-7 cells can also cause TOX3 up-regula-
tion. This growth factor has been shown to result in breast cancer
development and endocrine resistance during stabilization of
FOXA1 protein in MCF-7 cells. Furthermore, FOXA1 alters the pat-
tern of ER binding in poor outcome/metastatic ER+ breast cancer
leading to a situation similar to that in ER+ good outcome breast
cancer.
Conclusion: TOX3 gene amplification is associated with reduced
risk of the disease and metastasis. TOX3 significantly is associated
with increased breast cancer cell proliferation, migration, survival,
tumor development. Many studies confirm a key role for TOX3 in
breast cancer pathology. However, TOX3 plays dual and conflicting
roles in cancer initiation and progression which remains to be inves-
tigated.
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Introduction: The bacterial ghost (BG) system represents a novel
and progressive approach in the development of bacterial mediated
cancer immunotherapy. The empty inner space of BGs can be filled
with drugs, proteins, DNA, enzymes and other compounds. The
induced lysis process does not harm the essential structural compo-
nents of the bacteria, giving rise to immunologically active particles
capable of stimulating the host immune system and delivering spe-
cific antigen (Ag) to professional antigen-presenting cells (APCs)
or active substances to the target cells.
Production of bacterial ghosts: BGs are produced by expression
of cloned gene E from bacteriophage fX174 resulting to cell lysis in
Gram-negative bacteria, such as, Escherichia coli K12 strains, Kleb-
siella pneumoniae, Mannheimia (Pasteurella) haemolytica, Neisseria
meningitidis, Salmonella typhimurium, Vibrio cholera, Helicobacter
pylori, and others. Expression of gene E can be placed under tran-
scriptional control of either the thermo sensitive EpL/pR-cI857 pro-
moter, or under chemical inducible promoter repressor systems, like
lacPO or the tol expression system.
